Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAP regimen (palbociclib + venetoclax + azacitidine) in NUP98-R positive childhood AML
ChiCTR2300074396Phase 2Recruiting
- Sponsor
- Union Hospital
- Start
- Aug 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib, venetoclax and azacitidine in acute myeloid leukemia (AML), sponsored by Union Hospital. Primary endpoint: Remission rate after one course of VAP regimen treatment. Started Aug 2023; status: recruiting.
02
Drugs
palbociclibvenetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2300074396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074396.